Ahmedabad, Gujarat [India], May 27 (ANI): Leading pharmaceutical company Zydus Cadila said on Thursday that its net profit rose 73% year-on-year to Rs 679 million during the quarter ended March.
Earnings before interest, depreciation and taxes (EBIDTA) grew by 8% to 855 million euros during the fourth quarter of fiscal year 21, it said in a statement.
Total operating income of 3,847 million Spanish dollars increased by 3% compared to 3,752 million Spanish dollars in the fourth quarter of 2020.
The company’s business in the geography of India, which includes formulations of human health, consumer welfare and animal health business, recorded growth of 18 per cent, with revenues of € 1.772 billion.
The US formulations business recorded revenues of 1,509 million euros during the fourth quarter of fiscal 21. By strengthening its regulatory channel, the company filed 22 applications for additional new abbreviated drugs (ANDA) during the year to the U.S. Food and Drug Administration, bringing the cumulative applications to 412.
The company received 35 ANDA approvals during the year, accounting for a total of 317 product approvals.
Continuing its efforts in the fight against Covid-19 with diagnoses, therapeutics, and vaccines, Zydus Cadila released Virafin (Pegylated Interferon alpha-2b PegIFN) to treat moderate infection in adult patients during the fourth trimester.
ZyCoV-D, the company’s plasmid DNA vaccine, is in an advanced phase of phase three clinical trials and data is expected to be delivered to regulators in June. (ANI)